All AbMole products are for research use only, cannot be used for human consumption.
Vistusertib (AZD2014) is a novel dual mTORC1 and mTORC2 inhibitor with potential antineoplastic activity. Vistusertib (AZD2014) inhibits biomarkers pAKTSer473 and pNDRG1Thr346. Vistusertib (AZD2014) has broad antiproliferative activity across multiple tumour cell lines. Vistusertib (AZD2014) induces growth inhibition and cell death in breast cancer cell lines, including ER+ cell lines with acquired resistance to hormone therapy. Vistusertib (AZD2014) induces tumour growth inhibition against several xenograft models including a human primary explant model of ER+ breast cancer refractory to tamoxifen.
 |
Source | Cell Physiol Biochem (2018). Figure 4. AZD2014 |
| Method | Flow cytometric analysis | |
| Cell Lines | NSCLC cell | |
| Concentrations | - | |
| Incubation Time | 24 h | |
| Results | When mTOR was inhibited in anti-miR-99a-A549 cells by AZD2014, the cells became more sensitive to radiation than control cells and the levels of anti-apoptosis markers were reduced |
| Molecular Weight | 462.54 |
| Formula | C25H30N6O3 |
| CAS Number | 1009298-59-2 |
| Solubility (25°C) | DMSO 18 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related mTOR Products |
|---|
| RMC-4627
RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth. |
| RMC-4529
RMC-4529 has an IC50 value of 1.0 nM against p-4E-BP1-(T37/46) in mTOR kinase cellular assay. |
| WYE-687 dihydrochloride
WYE-687 dihydrochloride is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM. |
| Rapamycin-d3
Rapamycin-d3 |
| L-Leucine-d10
L-Leucine-d10 |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
